

**INSTRUCTION FOR USE**

(Summary of Product Characteristics)

**1 NAME OF THE MEDICINAL PRODUCT**

**OCTANATE 250**, 250 IU powder and solvent for solution for injection

**OCTANATE 500**, 500 IU powder and solvent for solution for injection

**OCTANATE 1000**, 1000 IU powder and solvent for solution for injection

**2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

OCTANATE 250 IU is presented as powder and solvent for solution for injection containing nominally 250 IU human coagulation factor VIII per vial.

The product contains approximately 50 IU\* per ml human coagulation factor VIII when reconstituted with 5 ml of solvent.

OCTANATE 500 IU is presented as powder and solvent for solution for injection containing nominally 500 IU human coagulation factor VIII per vial.

The product contains approximately 100 IU\* per ml human coagulation factor VIII when reconstituted with 5 ml of solvent.

OCTANATE 1000 IU is presented as powder and solvent for solution for injection containing nominally 1000 IU human coagulation factor VIII per vial.

The product contains approximately 200 IU\* per ml human coagulation factor VIII when reconstituted with 5 ml of solvent.

Produced from the plasma of human donors.

Excipient with known effect:

250 IU/vial: less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'

500 IU/vial and 1000 IU/vial: Sodium up to 1.75 mmol (40 mg) per dose

Sodium concentration after reconstitution: 125 – 175 mmol/l

For a full list of excipients, see section 6.1.

\*The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The mean specific activity of OCTANATE is  $\geq 100$  IU/mg protein.

**3 PHARMACEUTICAL FORM**

Powder and solvent for solution for injection.

A white or pale yellow powder or friable solid.

The solvent is a clear, colourless solution.

**4 CLINICAL PARTICULARS****4.1 Therapeutic indications**

Treatment and prevention of bleeding episodes in patients with hemophilia A (congenital or acquired FVIII deficiency), including previously treated patients (PTPs), previously untreated patients (PUPs) and patients undergoing major and minor surgical procedures; and for the treatment of inhibitors by Immune Tolerance Induction (ITI).

- Summary of Product Characteristics

4.2 Posology and method of administration

Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.

Posology

The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding, and on the patient’s clinical condition.

The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current World Health Organisation (WHO) international standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).

On-demand treatment

One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma. The calculation of the required dosage of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 1.5% to 2% of normal activity. The required dosage is determined using the following formula:

$$\text{Required units} = \text{body weight (kg)} \times \text{desired factor VIII rise (\%)} \text{ (IU/dl)} \times 0.5$$

The amount and frequency of administration should always be adjusted according to the clinical effectiveness in the individual patient.

In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:

Degree of haemorrhage/ Type of surgical procedure	Factor VIII level required (%) (IU/dl)	Frequency of doses (hours) / Duration of therapy (days)
<b>Haemorrhage</b>		
Early haemarthrosis, muscle bleeding or oral bleeding	20 – 40	Repeat every 12 to 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
More extensive haemarthrosis, muscle bleeding or haematoma	30 – 60	Repeat infusion every 12 to 24 hours for 3-4 days or more until pain and disability are resolved.
Life threatening haemorrhages	60 - 100	Repeat infusion every 8 to 24 hours until threat is resolved.
<b>Surgery</b>		
<i>Minor</i> including tooth extraction	30 – 60	Every 24 hours, at least 1 day, until healing is achieved.
<i>Major</i>	80 – 100 (pre- and postoperative)	Repeat infusion every 8 to 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a FVIII activity of 30% to 60%.

### Prophylaxis

For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dosage intervals or higher does may be necessary.

### Continuous infusion

Prior to surgery, a pharmacokinetic analysis should be performed to obtain an estimate of clearance.

The initial infusion rate can be calculated as follows: Clearance x desired steady state level = infusion rate (IU/kg/hr).

After the initial 24 hours of continuous infusion, the clearance should be calculated again every day using the steady state equation with the measured level and the known rate of infusion.

During the course of treatment, appropriate determination of factor VIII level is advised to guide the dose to be administered and the frequency of repeated infusions. In the case of major surgical interventions in particular, a precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries.

### Previously untreated patients

Clinical data on the use of Octanate in previously untreated patients (PUPs) are limited. Currently available data are described in section 5.1.

### Paediatric population

A clinical study which was conducted in 15 patients of 6 years of age or less did not identify any special dosage requirements for children.

### Immune tolerance induction

Interim data of an ongoing investigator initiated study to systematically document patients undergoing ITI therapy with OCTANATE are available. The OCTANATE dosing regime is case-dependent, under the direction of the treating center for each individual. Low responders (inhibitors < 5 BU) generally receive 50-100 IU FVIII/kg body weight daily, or every second day, and high responders (inhibitors ≥ 5 BU) 100-150 IU FVIII/kg body weight every 12 hours. Inhibitor titers are measured up to twice weekly for the initial 3 months and thereafter once per 3-month scheduled visit at the treatment center for the duration of therapy. Over 36 months, the outcome of ITI therapy is determined according to 3 sequential criteria, including negative inhibitor titre (< 0.6 BU), normalized FVIII recovery and normalized FVIII half life. In an interim analysis of the 69 patients so far treated with OCTANATE via ITI, 49 patients have completed the study. In the patients where the inhibitor was successfully eliminated, the monthly bleeding rates were significantly reduced.

### Method of administration

Intravenous use.

It is recommended not to administer more than 2–3 mL per minute.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients.

**4.4 Special warnings and precautions for use**Hypersensitivity

Allergic type hypersensitivity reactions are possible with Octanate. The product contains traces of human proteins other than factor VIII. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.

In case of shock, standard medical treatment of shock should be implemented.

Inhibitors

The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication of the treatment of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the exposure to anti-haemophilic factor VIII, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days.

Cases of recurrent inhibitor (low titre) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a previous history of inhibitor development. Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.

If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.

Catheter-related complications

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.

Transmissible agents

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped virus hepatitis A virus (HAV). The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. hemolytic anaemia).

Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived factor VIII products.

**- Summary of Product Characteristics**

It is strongly recommended that every time OCTANATE is administered, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free' for 250 IU/vial and contains up to 1.75 mmol sodium (40 mg) per dose for 500 IU/vial and dose 1000 IU/vial. To be taken into consideration by patients on a controlled sodium diet.

Paediatric population

The listed warnings and precautions apply to both adults and children.

**4.5 Interaction with other medicinal products and other forms of interaction**

No interactions of human coagulation factor VIII products with other medicinal products have been reported.

**4.6 Pregnancy and lactation**

Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and lactation only if clearly indicated.

**4.7 Effects on ability to drive and use machines**

Octanate has no or negligible influence on the ability to drive and use machines.

**4.8 Undesirable effects**Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, chest tightness, tingling, vomiting, wheezing) have been observed rarely, and may in some cases progress to severe anaphylaxis (including shock).

On rare occasions, fever has been observed.

Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with Octanate see section 5.1. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.

For safety information with respect to transmissible agents, see section 4.4.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).

Frequencies have been evaluated according to the following convention: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), not known (cannot be estimated from the available data).

- Summary of Product Characteristics

<u>MedDRA Standard System</u> <u>Organ Class</u>	<u>Adverse Reaction</u>	<u>Frequency</u>
Immune system disorders	Hypersensitivity	Rare
	Anaphylactic shock	Very rare
General disorders and administration site conditions	Pyrexia	Rare
Blood and lymphatic system disorders	FVIII Inhibition	Uncommon (PTPs)*
		Very common (PUP)*
Investigations	Anti factor VIII antibody positive	Rare

\* Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients

Paediatric population

Frequency, type and severity of adverse reactions in children are the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medical product is important. It allows continued monitoring of the benefit/risk balance of the medical product. Healthcare professionals are asked to report any suspected adverse reactions.

**4.9 Overdose**

No case of overdose has been reported.

**5 PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII

ATC-Code: B02BD02

The factor VIII/ von Willebrand factor complex consists of two molecules (FVIII and vWF) with different physiological functions. When infused into a haemophiliac patient, factor VIII binds to von Willebrand factor in the patient's circulation.

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.

Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles, or internal organs, either spontaneously or as a results of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Previously untreated patients

In an ongoing clinical trial in previously untreated patients (PUPs), 3 out of 39 (7.6%) PUPs treated with Octanate on-demand developed inhibitors with a titre above 5 BU. One patient developed inhibitors with a titre below 5 BU. Two cases (5.1%) were of clinical relevance; the remaining two subjects

- Summary of Product Characteristics

displayed inhibitors that disappeared spontaneously without an Octanate dose change. All inhibitors developed with on-demand treatment and before exposure day 50.

35 PUPs had a baseline FVIII activity < 1% and 4 PUPs had ≤2% FVIII:C. At the time point of the interim analysis, there were 34 patients who had already 20 or more exposure days to Octanate and 30 patients with 50 or more exposure days to Octanate. No inhibitors were observed in PUPs receiving prophylaxis with Octanate. During the study, 12 PUPs underwent 14 surgical procedures. The median age at the first exposure was 7 months (range 3 days to 67 months). The median number of exposure days in the clinical trial was 100 (range 1-553).

Octanate is being assessed for induction of immune tolerance induction (ITI) therapy in an ongoing observational clinical study.

In an interim analysis of the 69 patients so far treated with Octanate via ITI, 49 patients have completed the study. In the patients where the inhibitor was successfully eliminated, the monthly bleeding rates were significantly reduced.

**5.2 Pharmacokinetic properties**

Human plasma coagulation factor VIII (from the concentrate) is a normal constituent of the human plasma and acts like the endogenous factor VIII. After injection of the product, approximately two-thirds to three-quarter of the factor VIII remain in the circulation. The level of factor VIII activity reached in the plasma should be between 80% - 120% of the predicted factor VIII activity.

Plasma factor VIII activity decreases by a two-phase exponential decay. In the initial phase, distribution between the intravascular and other compartments (body fluids) occurs with a half-life of elimination from the plasma of 3 to 6 hours. In the subsequent slower phase (which probably reflects the consumption of factor VIII), the half-life varies between 8 to 20 hours, with an average of 12 hours. This corresponds to the true biological half-life.

For OCTANATE the following results were achieved for two pharmacokinetic studies with 10 and 14 haemophilia A patients, respectively:

	Recovery (% x IU <sup>-1</sup> x kg)	AUC*norm (% x h x IU <sup>-1</sup> x kg)	Half-life (h)	MRT* (h)	Clearance (ml x h <sup>-1</sup> x kg)
Study 1, n = 10 Mean ± SD*	2.4 ± 0.36	45.5 ± 17.2	14.3 ± 4.01	19.6 ± 6.05	2.6 ± 1.21
Study 2, n = 14 Mean ± SD*	2.4 ± 0.25	33.4 ± 8.50	12.6 ± 3.03	16.6 ± 3.73	3.2 ± 0.88

AUC\* = area under the curve,  
MRT\* = mean residence time,  
SD\* = standard deviation

**5.3 Preclinical safety data**

Toxicological data available on tri-n-butylphosphate (TNBP) and polysorbate 80 (tween 80), the solvent/detergent reagents used in the SD method of viral inactivation during manufacture of OCTANATE, although limited for the latter, indicate that adverse effects are unlikely at the anticipated human exposures.

Even doses of several times the recommended human dosage per kilogram body weight of these reagents show no toxic effects on laboratory animals. No mutagenic potential was observed for either of the two substances.

**6 PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**



**- Summary of Product Characteristics**

- Powder: - Sodium citrate  
- Sodium chloride  
- Calcium chloride  
- Glycine
- Solvent: -Water for injections

**6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Only the provided injection or infusion sets should be used, because treatment failure can occur as a consequence of human coagulation factor VIII adsorption to the internal surface of some injection/infusion equipment.

**6.3 Shelf life**

Do not use after the expiry date stated on the label.

The reconstituted solution must be used immediately and for single use only.

**6.4 Special precautions for storage**

Store at 2°C - 25°C.

Do not freeze.

Keep the vials in the outer carton in order to protect from light.

For storage conditions of the reconstituted medicinal product, see section 6.3.

**6.5 Nature and contents of container**

Powder in a vial (type I glass), with a stopper (halobutyl rubber), and a flip off cap; solvent in a vial (type I glass), with a stopper (halobutyl rubber), and a flip off cap; one disposable syringe, one double ended needle, one filter needle, one injection needle, and two alcohol swabs.

The available pack sizes differ in the amount of human blood coagulation factor VIII/ solvent:

OCTANATE 250 IU: reconstitution with 5 ml of solvent

OCTANATE 500 IU: reconstitution with 5 ml of solvent

OCTANATE 1000 IU: reconstitution with 5 ml of solvent

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

**Please read all the instructions and follow them carefully!**

**During the procedure described below, sterility must be maintained!**

**Instructions for reconstitution:**

1. Allow the solvent (Water for Injections) and the concentrate in the closed vials to reach room temperature. This temperature should be maintained during reconstitution.  
If a water bath is used for warming, care must be taken to avoid water coming into contact with the rubber stoppers or the caps of the vials. The temperature of the water bath should not exceed 37°C.
2. Remove the caps from the concentrate vial and the water vial and clean the rubber stoppers with an alcohol swab.
3. Remove the protective cover from the short end of the double-ended needle, making sure not to touch the exposed tip of the needle.



**- Summary of Product Characteristics**

Then perforate the centre of the water vial rubber stopper with the vertically held needle.

In order to withdraw the fluid from the water vial completely, the needle must be introduced into the rubber stopper in such a way that it just penetrates the stopper and is visible in the vial.

4. Remove the protective cover from the other, long end of the double-ended needle, making sure not to touch the exposed tip of the needle.

Hold the water vial upside-down above the upright concentrate vial and quickly perforate the centre of the concentrate vial rubber stopper with the needle. The vacuum inside the concentrate vial draws in the water.

5. Remove the double-ended needle with the empty water vial from the concentrate vial, then slowly rotate the vial until the concentrate is completely dissolved. Octanate dissolves quickly at room temperature to a clear solution. The reconstitution time is less than 10 minutes at room temperature.

After reconstitution with the supplied solvent, Octanate is administered intravenously. The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have deposits. Reconstituted products should be inspected visually for particulate matter and discoloration prior to administration.

The reconstituted solution must be used immediately and on one occasion only.

**Instructions for injection:**

As a precautionary measure, the patients pulse rate should be measured before and during the factor VIII injection. If a marked increase in the pulse rate occurs the injection speed must be reduced or the administration must be interrupted.

1. After the concentrate has been reconstituted in the manner described above, remove the protective cover from the filter needle and perforate the rubber stopper of the concentrate vial.
2. Remove the cap of the filter needle and attach the syringe.
3. Turn the vial with the attached syringe upside-down and draw the solution up into the syringe.
4. Disinfect the intended injection site with an alcohol swab.
5. Remove the filter needle from the syringe and attach the injection needle to the syringe instead.
6. Inject the solution intravenously at a slow speed of 2 - 3 ml per minute.

Patients using more than one vial of OCTANATE concentrate may use the same injection needle and syringe, but the filter needle is for single use only. Always use a filter needle when drawing up the preparation into a syringe.

Any unused product or waste material should be disposed of in accordance with local requirements.

**7     MARKETING AUTHORISATION HOLDER****7.1   Marketing authorisation holder**

OCTAPHARMA AG  
Seidenstrasse 2  
CH-8853 Lachen  
Switzerland

**7.2   Manufacturer**

Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria  
or  
Octapharma S.A.S., Lingolsheim, France  
or  
Octapharma AB, Stockholm, Sweden

**8     DATE OF REVISION OF THE TEXT**

April 2018

**9 LEGAL CATEGORY**  
For prescription only.